- To be eligible for enrollment in this study, patients must be prescribed oral Medrol®
tablets (4mg and 16 mg) for acute asthma as per the locally approved prescribing
information. The prescription of Medrol® will be separated from the decision to
include the patient in the study.
- Medrol® tablets, will be prescribed to the patient by the physician according to
his/her usual practice. The decision to prescribe Medrol® tablet will necessarily
precede and will be independent of the decision to enroll patient into the study. Only
those patients who have been prescribed Medrol® tablets will be evaluated for their
potential eligibility for the study
- Only those patients, who are ready and willing to sign an informed consent, will be
included in the study
- Subject can be contacted through telephone
- Based upon history or physical exam in the emergency department (ED) or Clinic,
subjects with known or suspected cause of pulmonary symptoms other than asthma, such
as COPD, CHF, pneumonia, pulmonary embolism, or angioedema
- Any contraindication to Medrol tablet use. Contraindications of Medrol use are
systemic fungal infections and known hypersensitivity to components